IRVINE, CA--(Marketwired - May 24, 2016) - Proove Biosciences, Inc., the commercial and research leader in personalized pain medicine, is pleased to announce it has received accreditation from the College of American Pathologists (CAP). This accreditation is an important milestone for the company's lab, further confirming the impeccable quality of its testing. As a worldwide leader in the research, investigation, and development of evidence-based and patent-protected genetic testing, Proove Biosciences helps physicians individualize -- and optimize -- pain medicine selection and dosing in order to improve outcomes for patients, providers, and insurers alike. With the designation, Proove is able to enter into contracts with federal government organizations and national payers that require such accreditation.

Brian Meshkin, Founder and CEO of Proove Biosciences, offers comment on the recognition: "Since launching in 2009, Proove has pioneered the delivery of proof to improve decisions related to the nation's most prevalent and expensive healthcare condition -- chronic pain. With this validation from CAP, Proove can now offer solutions to millions in order to help our nation tackle the crippling epidemics of prescription opioid abuse, unresolved pain, and disability." Supported by an advisory board of the world's leading medical experts, the company's patented bioinformatics platform for collecting, storing, analyzing, and integrating biological and genetic information is changing the healthcare industry.

CAP, considered to be the most comprehensive and scientifically-endorsed laboratory standard, has truly opened a new door for Proove Biosciences -- which has for years been revolutionizing personalized medicine through its proprietary platform that allows prescribers to evaluate pain tolerance, assess patient drug metabolism, predict response and immunity risks to opioid and non-opioid pain medication, and identify genetic predisposition for opioid dependence and addiction. The game-changing accreditation allows Proove Biosciences to render services to federally sponsored entities such as the VA, Military Health Service, NIDA/NIH, GSA, and OPM.

"Our patented platform has a huge impact on public health. We are on a mission to bring our predictive methods to a new, vital audience of doctors and patients," adds Meshkin. "Proove is extremely grateful to CAP for officially recognizing our high quality and standards." This endorsement is just the beginning for Proove Biosciences, which plans to pursue a New York State accreditation, along with other ISO accreditations that will prepare the company for a future when the FDA extends further regulations of laboratory-developed tests (LDTs).

To learn more about Proove Biosciences, visit www.proove.com.

About Proove Biosciences: Proove Biosciences -- the world's largest Healthcare Decision Company™ -- is the commercial and educational leader in the research, investigation and development of patent-protected tests that combine genetic and clinical data into reports which enable physicians to personalize -- and optimize -- medicine selection and dosing in order to improve outcomes for patients, providers and insurers alike. Backed by science, driven by data, confirmed with proof and supported by leading medical experts and institutions across the globe, Proove is revolutionizing personalized medicine. With a patented bioinformatics platform that delivers therapy-defining information allowing prescribers to evaluate pain tolerance, assess patient drug metabolism, predict response and immunity to opioid and non-opioid pain medication, and identify risk for dependence and addiction, Proove is providing the most technologically advanced solutions to enable accurate and evidence-based medical decision-making rather than "trial-and-error" approaches. Proove helps reduce the risk of treatment failure, decrease costs to insurers and relieve society of the emotional and financial burdens associated with addiction. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).